Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 21,046 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Results available

Evaluate Pharmacokinetics and Safety of Slow Release DHEA

NCT05623059
Conditions
Asthma, Genotype
Interventions
Slow Release DHEA
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Pulmonary Sarcoidosis
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Albany, New York • Cleveland, Ohio
Conditions
Myasthenia Gravis, Ocular
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more
Conditions
Breast Cancer
Interventions
Live Biobank
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Conditions
Hair Loss
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional

α-TEA in Advanced Cancer

NCT02192346
Conditions
Metastatic Carcinoma, Metastatic Sarcoma, Metastatic Lymphoma
Interventions
2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA, 9.6 mg/kg α-TEA, 12 mg/kg α-TEA, 16.8 mg/kg α-TEA, 19.2 mg/kg α-TEA, 22.3 mg/kg α-TEA, 26.8 mg/kg α-TEA
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Clackamas, Oregon • Newberg, Oregon • Oregon City, Oregon + 1 more
Conditions
Multiple Myeloma
Interventions
Melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Conditions
Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Interventions
Mindfulness-based Music Therapy (MBMT), Mindfulness Meditation (MM)
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Terminated Not applicable Interventional

Control:Diabetes Pilot Study I

NCT04158921
Conditions
Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions
Control:Diabetes mobile app
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Rheumatoid Arthritis
Interventions
adalimumab (up to 9 months exposure), methotrexate
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
North Chicago, Illinois
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With HAM/TSP

NCT00001778
Conditions
HTLV-I Infection, Tropical Spastic Paraparesis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
X-Linked Combined Immunodeficiency Diseases
Interventions
CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT, Palifermin, Busulfan
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Type 1 Diabetes, Pregnancy
Interventions
Automated Insulin Delivery (AID)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • Rochester, Minnesota + 1 more
Conditions
Non Hodgkin Lymphoma
Interventions
UCD19 CAR T Cells
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, Clofarabine, Allogeneic Stem Cell Infusion
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Asthma
Interventions
Sensor cap system for inhalers, App for SmartPhone, Motivational interviews, Telehealth clinic visits
Device · Other · Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Multiple Myeloma
Interventions
CDC-501
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more
Conditions
Multiple Myeloma, Refractory
Interventions
Pembrolizumab, Belantamab mafodotin, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Conditions
LAM, Lymphangioleiomyomatosis
Interventions
Sirolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 5 more
Conditions
HIV Infections
Interventions
Raluridine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Maitland, Florida + 4 more
Conditions
Immune Thrombocytopenic Purpura
Interventions
rituxan
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Vahalla, New York
Completed No phase listed Observational Accepts healthy volunteers

HIV and Cardiovascular Risk

NCT00465426
Conditions
HIV Infections, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts